Login to Your Account



Other News To Note


Tuesday, June 18, 2013

• Transition Therapeutics Inc., of Toronto, said Eli Lilly and Co., of Indianapolis, exercised its option to assume all development and commercialization rights to Type II diabetes drug candidate TT-401.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription